
Patients with wet age-related macular degeneration who were switched from aflibercept alone to a combination of aflibercept and UBX1325 at week 24 maintained vision gains through 48 weeks in part B of the phase 2 ENVISION study.
“The ENVISION study shows that patients with wet AMD who switch from anti-VEGF to UBX1325 can maintain visual acuity with a significant reduction in anti-VEGF treatment burden,” Anirvan Ghosh, PhD, CEO of Unity Biotechnology, said in a press release. “Patients with more severe disease may benefit from a combination of aflibercept and UBX1325.”